Eton Pharmaceuticals Inc. (ETON) and Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) Contrasting side by side

As Biotechnology companies, Eton Pharmaceuticals Inc. (NASDAQ:ETON) and Rocket Pharmaceuticals Inc. (NASDAQ:RCKT) are our subject to contrast. And more specifically their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Eton Pharmaceuticals Inc. 7 222.04 N/A -2.36 0.00
Rocket Pharmaceuticals Inc. 15 0.00 N/A -1.89 0.00

In table 1 we can see Eton Pharmaceuticals Inc. and Rocket Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.


Table 2 provides Eton Pharmaceuticals Inc. and Rocket Pharmaceuticals Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Eton Pharmaceuticals Inc. 0.00% 0% -238.9%
Rocket Pharmaceuticals Inc. 0.00% -46.8% -35.1%


5.9 and 5.9 are the respective Current Ratio and a Quick Ratio of Eton Pharmaceuticals Inc. Its rival Rocket Pharmaceuticals Inc.’s Current and Quick Ratios are 9.7 and 9.7 respectively. Rocket Pharmaceuticals Inc. has a better chance of clearing its pay short and long-term debts than Eton Pharmaceuticals Inc.

Analyst Ratings

The table given features the ratings and recommendations for Eton Pharmaceuticals Inc. and Rocket Pharmaceuticals Inc.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Eton Pharmaceuticals Inc. 0 0 0 0.00
Rocket Pharmaceuticals Inc. 0 0 1 3.00

Competitively Rocket Pharmaceuticals Inc. has an average price target of $37, with potential upside of 150.34%.

Insider and Institutional Ownership

Institutional investors owned 9.2% of Eton Pharmaceuticals Inc. shares and 87.9% of Rocket Pharmaceuticals Inc. shares. About 5.8% of Eton Pharmaceuticals Inc.’s share are owned by insiders. Comparatively, Rocket Pharmaceuticals Inc. has 1.6% of it’s share owned by insiders.


In this table we provide the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Eton Pharmaceuticals Inc. -2.56% -18.8% -17.7% -1.77% 0% -0.49%
Rocket Pharmaceuticals Inc. -4.32% -12.81% -33.11% -12.5% -38.11% -17.81%

For the past year Eton Pharmaceuticals Inc.’s stock price has smaller decline than Rocket Pharmaceuticals Inc.


Rocket Pharmaceuticals Inc. beats on 5 of the 8 factors Eton Pharmaceuticals Inc.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating pediatric diseases. It has two lentiviral vector (LVV) programs under clinical testing to treat fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells; and three LVV programs for the treatment of other rare genetic diseases, as well as an adeno-associated viral vector program, which is under preclinical development. The company has collaboration agreements with Lund University, Sweden; and Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas. The company is headquartered in New York, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.